1. A 49-year-old man with heavy alcohol use presents with jaundice and tender hepatomegaly. His Maddrey discriminant function (a prognostic score from prothrombin time and bilirubin) is 55. Blood and urine cultures are negative, chest imaging is clear, and diagnostic paracentesis excludes spontaneous bacterial peritonitis. There is no gastrointestinal bleeding. Based on the evidence from the STOPAH (Steroids or Pentoxifylline for Alcoholic Hepatitis) trial, which pharmacological therapy offers a demonstrated short-term mortality benefit?
A) Pentoxifylline, because it reduces hepatorenal syndrome and mortality
B) No pharmacotherapy, because neither agent affects mortality
C) Prednisolone 40 mg orally daily, because it reduced 28-day mortality whereas pentoxifylline did not
D) Combined prednisolone and pentoxifylline, because the combination is additive
E) Intravenous methylprednisolone, because it is superior to oral prednisolone
ANSWER: C
Rationale:
This patient has severe alcoholic hepatitis by a discriminant function of 55 with no contraindication, and the STOPAH trial showed that prednisolone reduced 28-day mortality whereas pentoxifylline did not, so oral prednisolone 40 mg daily is the evidence-based choice.
Option A: Option A is incorrect because pentoxifylline failed to reduce mortality and failed to reduce hepatorenal syndrome in STOPAH.
Option B: Option B is incorrect because corticosteroids do confer a short-term mortality benefit in this severe, contraindication-free patient.
Option D: Option D is incorrect because there is no demonstrated additive benefit from combining pentoxifylline with prednisolone.
Option E: Option E is incorrect because oral prednisolone is the preferred formulation and is not inferior to intravenous methylprednisolone in this setting.
2. A 52-year-old woman with severe alcoholic hepatitis has completed 7 days of prednisolone. Her day-7 Lille score (a model predicting corticosteroid response) is 0.50, and she has no active infection or bleeding. What is the most appropriate next step?
A) Discontinue prednisolone, because a Lille score of 0.45 or above defines non-response with no survival benefit from continuing
B) Continue prednisolone for the full 28 days, because she is responding well
C) Increase the prednisolone dose to overcome non-response
D) Switch to intravenous methylprednisolone to improve the response
E) Extend prednisolone beyond 28 days to allow more time for benefit
ANSWER: A
Rationale:
A Lille score of 0.45 or greater at day 7 defines non-response and predicts a high 6-month mortality, so continuing prednisolone offers no survival benefit while adding immunosuppression risk; the appropriate step is to discontinue it.
Option B: Option B is incorrect because a score of 0.50 indicates non-response, not a good response, so completing 28 days is not justified.
Option C: Option C is incorrect because no Lille category calls for dose escalation, and increasing steroids in a non-responder adds risk without benefit.
Option D: Option D is incorrect because switching to an intravenous formulation does not reverse non-response, and oral prednisolone is the preferred formulation.
Option E: Option E is incorrect because extending therapy in a defined non-responder prolongs immunosuppression with no expected benefit.
3. A 45-year-old man with severe alcoholic hepatitis and a Maddrey discriminant function of 41 has moderate ascites on examination. Before any corticosteroid is started, which step is most essential in his pre-treatment workup?
A) Begin prednisolone immediately and screen for infection afterward
B) Start prophylactic antifungal therapy and proceed without further testing
C) Obtain a fasting lipid panel and thyroid function tests
D) Perform upper endoscopy to exclude varices before any other step
E) Perform diagnostic paracentesis to exclude spontaneous bacterial peritonitis, because active untreated infection is an absolute contraindication to steroids
ANSWER: E
Rationale:
In a patient with ascites being considered for corticosteroids, diagnostic paracentesis is essential to exclude spontaneous bacterial peritonitis, because active untreated infection is an absolute contraindication to steroid therapy and would change management.
Option A: Option A is incorrect because infection must be excluded before, not after, starting steroids, given the contraindication.
Option B: Option B is incorrect because prophylactic antifungals are not universally mandated and do not substitute for excluding an active infection.
Option C: Option C is incorrect because lipid and thyroid testing are not part of the pre-steroid infection screen.
Option D: Option D is incorrect because, while variceal assessment matters in cirrhosis, excluding spontaneous bacterial peritonitis in a patient with ascites is the essential infection-screening step before steroids.
4. A 58-year-old woman with biopsy-proven MASH (metabolic dysfunction-associated steatohepatitis) and stage F3 fibrosis, but no cirrhosis, has not improved with sustained lifestyle change. Her Child-Pugh assessment is class A. Based on the MAESTRO-NASH trial, which agent is specifically approved for her disease stage?
A) Obeticholic acid, because it is approved for MASH fibrosis
B) Resmetirom, a selective thyroid hormone receptor-beta agonist approved for MASH with stage F2 to F3 fibrosis, which met its co-primary endpoints of MASH resolution and fibrosis improvement
C) High-dose ursodeoxycholic acid, because it reverses fibrosis in MASH
D) Lactulose, because it reduces hepatic inflammation
E) Pentoxifylline, because it has anti-fibrotic benefit in MASH
ANSWER: B
Rationale:
Resmetirom is a selective thyroid hormone receptor-beta agonist approved for MASH with moderate-to-severe fibrosis, stages F2 to F3, and in the MAESTRO-NASH trial it met both co-primary endpoints of MASH resolution and at least one-stage fibrosis improvement; this Child-Pugh A, non-cirrhotic F3 patient fits the indication.
Option A: Option A is incorrect because obeticholic acid is a therapy for cholestatic disease, not an approved MASH fibrosis treatment.
Option C: Option C is incorrect because high-dose ursodeoxycholic acid does not reverse MASH fibrosis and is harmful in the cholestatic settings discussed.
Option D: Option D is incorrect because lactulose treats hepatic encephalopathy and has no role in MASH.
Option E: Option E is incorrect because pentoxifylline has no established anti-fibrotic benefit and is not used for MASH.
5. A 55-year-old man with biopsy-confirmed MASH and type 2 diabetes, with no history of heart failure, is being considered for pharmacotherapy that also helps his glycemic control. Based on the PIVENS (Pioglitazone versus Vitamin E versus placebo for NASH) trial, which agent is a reasonable choice, and what counseling point is essential?
A) Vitamin E, with counseling about its insulin-sensitizing effect
B) Obeticholic acid, with counseling about weight loss
C) Resmetirom, with counseling that it is approved for cirrhosis
D) Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist that improved liver histology in PIVENS, with counseling that weight gain is nearly universal
E) Lactulose, with counseling about ammonia reduction
ANSWER: D
Rationale:
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, improved the activity score and increased histological resolution of steatohepatitis in the PIVENS trial and is a reasonable option for a MASH patient with type 2 diabetes and no heart failure, but counseling that weight gain of several kilograms is nearly universal is essential.
Option A: Option A is incorrect because vitamin E is an antioxidant, not an insulin sensitizer, and that counseling point misstates its mechanism.
Option B: Option B is incorrect because obeticholic acid is a cholestatic-disease therapy and is associated with pruritus, not a weight-loss counseling point.
Option C: Option C is incorrect because resmetirom is not approved for cirrhosis, so that counseling statement is wrong.
Option E: Option E is incorrect because lactulose treats hepatic encephalopathy and has no role in MASH.
6. A 60-year-old woman with primary biliary cholangitis (an autoimmune disease of the small intrahepatic bile ducts) has taken ursodeoxycholic acid for 12 months, but her alkaline phosphatase remains 2.5 times the upper limit of normal. She has compensated, Child-Pugh class A disease. Based on the POISE trial, which second-line agent is appropriate, and what is the key counseling point?
A) Obeticholic acid, a farnesoid X receptor agonist that reduced alkaline phosphatase and bilirubin in POISE, with counseling that pruritus is the principal dose-limiting effect
B) Bezafibrate as the established first-line replacement for ursodeoxycholic acid
C) Resmetirom, because it is indicated for primary biliary cholangitis
D) High-dose ursodeoxycholic acid at 30 mg/kg/day, which is preferred for inadequate responders
E) Lactulose, because it improves cholestatic biochemistry
ANSWER: A
Rationale:
For an inadequate responder to ursodeoxycholic acid with compensated Child-Pugh A disease, obeticholic acid is the established second-line farnesoid X receptor agonist that reduced alkaline phosphatase and total bilirubin in the POISE trial, and the key counseling point is that pruritus is its principal dose-limiting adverse effect.
Option B: Option B is incorrect because bezafibrate is a third-line option, not a first-line replacement for ursodeoxycholic acid.
Option C: Option C is incorrect because resmetirom is indicated for MASH, not primary biliary cholangitis.
Option D: Option D is incorrect because high-dose ursodeoxycholic acid is not a validated strategy for inadequate responders and is harmful in cholestatic disease.
Option E: Option E is incorrect because lactulose treats hepatic encephalopathy and does not improve cholestatic biochemistry.
7. A 63-year-old woman with primary biliary cholangitis had an inadequate response to ursodeoxycholic acid, and obeticholic acid was discontinued because it caused intolerable pruritus. Based on the BEZURSO trial, which third-line agent is most appropriate, and why is it especially suited to her?
A) Re-trial of obeticholic acid at a higher dose
B) Naltrexone as a disease-modifying biochemical therapy
C) Bezafibrate added to ursodeoxycholic acid, a peroxisome proliferator-activated receptor-alpha agonist that produced biochemical response in BEZURSO and tends to improve pruritus
D) High-dose ursodeoxycholic acid monotherapy
E) Cholestyramine as definitive biochemical therapy
ANSWER: C
Rationale:
In the BEZURSO trial, bezafibrate combined with ursodeoxycholic acid produced a significant biochemical response and improved pruritus, making it the appropriate third-line choice for a patient who could not tolerate obeticholic acid specifically because of severe itch.
Option A: Option A is incorrect because re-trialing obeticholic acid at a higher dose would worsen the pruritus that forced its discontinuation.
Option B: Option B is incorrect because naltrexone is a symptomatic antipruritic acting through central opioid antagonism, not a disease-modifying biochemical therapy.
Option D: Option D is incorrect because high-dose ursodeoxycholic acid monotherapy is not a validated strategy for inadequate responders and is harmful in cholestatic disease.
Option E: Option E is incorrect because cholestyramine is a first-line antipruritic sequestrant, not a definitive therapy that normalizes cholestatic biochemistry.
8. A 38-year-old man with primary sclerosing cholangitis (PSC: fibro-inflammatory stricturing of intrahepatic and extrahepatic bile ducts) and ulcerative colitis develops rising bilirubin, pruritus, and intermittent fevers. Cholangiography shows a dominant extrahepatic stricture. What is the most appropriate management?
A) Start high-dose ursodeoxycholic acid at 30 mg/kg/day to reverse the stricture
B) Begin obeticholic acid to halt biliary fibrosis
C) Initiate pentoxifylline for its anti-fibrotic effect
D) Start standard-dose ursodeoxycholic acid, which improves transplant-free survival in PSC
E) Refer for endoscopic retrograde cholangiopancreatography with balloon dilation or short-term stenting of the dominant stricture, and maintain cancer surveillance
ANSWER: E
Rationale:
In primary sclerosing cholangitis, a dominant stricture causing rising bilirubin and cholangitis is managed endoscopically with balloon dilation or short-term stenting, while cholangiocarcinoma and colorectal cancer surveillance continue, because no pharmacological agent halts the disease.
Option A: Option A is incorrect because high-dose ursodeoxycholic acid is actively contraindicated in PSC owing to increased adverse events and does not reverse strictures.
Option B: Option B is incorrect because obeticholic acid does not halt biliary fibrosis in PSC.
Option C: Option C is incorrect because pentoxifylline has no established anti-fibrotic role here.
Option D: Option D is incorrect because standard-dose ursodeoxycholic acid has not been shown to improve transplant-free survival in PSC.
9. A 64-year-old man with cirrhosis has had two hospitalizations for overt hepatic encephalopathy (HE: brain dysfunction from liver insufficiency and portosystemic shunting) over 4 months despite adherent lactulose therapy. Based on the landmark rifaximin trial in recurrent overt encephalopathy, what is the best long-term step?
A) Replace lactulose with rifaximin monotherapy
B) Add rifaximin 550 mg twice daily to ongoing lactulose, because in the registration trial it reduced HE breakthrough episodes and HE-related hospitalizations
C) Replace lactulose with neomycin for broader systemic coverage
D) Stop lactulose, since recurrence proves it is ineffective
E) Start a benzodiazepine to prevent future episodes
ANSWER: B
Rationale:
In the landmark trial of rifaximin added to background lactulose for recurrent overt encephalopathy, rifaximin 550 mg twice daily reduced the risk of breakthrough episodes and HE-related hospitalizations, so adding it to ongoing lactulose is the appropriate secondary prophylaxis.
Option A: Option A is incorrect because rifaximin is add-on therapy, not a monotherapy replacement for lactulose.
Option C: Option C is incorrect because a systemic antibiotic carries toxicity and resistance concerns that the non-absorbed rifaximin avoids, and replacing lactulose removes its benefit.
Option D: Option D is incorrect because recurrence on lactulose calls for adding rifaximin, not abandoning effective therapy.
Option E: Option E is incorrect because benzodiazepines precipitate encephalopathy and have no prophylactic role.
10. A 57-year-old woman with cirrhosis is brought in confused with asterixis. She was recently started on an opioid for back pain and has not had a bowel movement in 4 days. She is rousable and protecting her airway. What is the most appropriate immediate management?
A) Withhold lactulose until a definitive ammonia level returns
B) Give a benzodiazepine to calm her agitation
C) Increase her diuretic dose to enhance ammonia clearance
D) Identify and correct the precipitants by stopping the opioid and treating the constipation, and start lactulose titrated to two to three soft stools daily
E) List her for liver transplantation as the immediate next step
ANSWER: D
Rationale:
Acute overt encephalopathy is managed by identifying and correcting precipitants, here an offending opioid and constipation, while starting lactulose titrated to two to three soft stools per day; precipitant correction is the single most impactful intervention.
Option A: Option A is incorrect because therapy should not be delayed for an ammonia level, which does not guide acute treatment.
Option B: Option B is incorrect because benzodiazepines are themselves precipitants of encephalopathy and would worsen her.
Option C: Option C is incorrect because increasing diuresis risks the electrolyte and acid-base disturbances that precipitate encephalopathy.
Option E: Option E is incorrect because transplant listing is not the immediate step for a reversible precipitated episode.
11. A 61-year-old man with cirrhosis presents with grade IV hepatic encephalopathy: he is poorly responsive, cannot protect his airway, and has a depressed gag reflex. The team is preparing to give lactulose. What is the most appropriate priority before administering oral therapy?
A) Secure the airway with intensive care unit evaluation and endotracheal intubation for aspiration prevention before oral lactulose is given, using a retention enema if needed in the interim
B) Force oral lactulose immediately regardless of his level of consciousness
C) Administer a benzodiazepine to facilitate cooperation with oral dosing
D) Withhold all encephalopathy therapy until he wakes on his own
E) Begin high-dose intravenous ursodeoxycholic acid as first-line therapy
ANSWER: A
Rationale:
Grade III to IV encephalopathy with depressed consciousness and an unprotected airway requires intensive care unit evaluation and often endotracheal intubation for aspiration prevention before oral lactulose can be given safely, with a retention enema used to deliver lactulose in the interim.
Option B: Option B is incorrect because forcing oral lactulose in a patient who cannot protect his airway risks aspiration.
Option C: Option C is incorrect because benzodiazepines precipitate and worsen encephalopathy and must be avoided.
Option D: Option D is incorrect because withholding therapy abandons treatment of a life-threatening condition.
Option E: Option E is incorrect because intravenous ursodeoxycholic acid is not a therapy for hepatic encephalopathy.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.